r-pharm.com Open in urlscan Pro
195.210.21.58  Public Scan

Form analysis
0 forms found in the DOM

Text Content

About
ManagementBusiness ethicsQuality control
Medications
Research and development
Production
Partnership
storage facilities
Social responsibility
Charity
Media center
Contacts
Management
Business ethics
Quality control
storage facilities
Charity
rus



COMPREHENSIVE HEALTHCARE SOLUTIONS

We specialize in research, development and production of pharmaceuticals,
laboratory equipment and medical devices

We focus on the release of following medications:
Oncological
Antiviral
Autoimmune
Orphan drugs
Pulmonological
Others


Production


Partnerships


ArlansaArtlegiaAtazanavir-TLCapecitabine-TLCinacalcet-TLEfavirenz-TLEmtricitabine-TLFemorixFluconazoleGefitinib-TLGlatirateGranisetronGranisetron-TLIsentressKalimateKanarbKoronavirLamivudin-ZTSNevirapine-TLOlanzapine-TLOndansetronPemetrexed-TLPomalidomide-TLQuetiapineReddytuxSaquinavir-TLSpectracefTemozolomide-TLTenofovir-TLVibativ
ArlansaArtlegiaAtazanavir-TLCapecitabine-TLCinacalcet-TLEfavirenz-TLEmtricitabine-TLFemorixFluconazoleGefitinib-TLGlatirateGranisetronGranisetron-TLIsentressKalimateKanarbKoronavirLamivudin-ZTSNevirapine-TLOlanzapine-TLOndansetronPemetrexed-TLPomalidomide-TLQuetiapineReddytuxSaquinavir-TLSpectracefTemozolomide-TLTenofovir-TLVibativ

We build innovations in the healthcare industry


 * 2016 — Market launch of a direct antiviral drug for the treatment of
   hepatitis C
 * 2020 — Market launch of a biotech drug for the treatment of rheumatoid
   arthritis





Pipeline


100+
medicines in pipeline
40+
active clinical trials


WE EXPLORE MODERN METHODS OF HEALTH PROTECTION



11
state-of-the-art plants

5000+
employees


NEWS

R-Pharm to Develop Original Medicine for the Treatment of Familial Mediterranean
Fever in Turkey Together with TRPharm
13 March
R-Pharm and the Federal Research Center of the Russian Academy of Sciences will
develop a drug for the treatment of depression and a number of neurodegenerative
diseases
22 December 2022
R-Pharm financed the establishment of a laboratory of the Russian Academy
of Sciences for the development of glycovaccines
28 November 2022
Clinical trials in Russia and Azerbaijan demonstrated safety of AstraZeneca
and Sputnik Light vaccines combination
14 February 2022
Phase 3 clinical trial results of Coronavir (favipiravir) published in US
Journal
13 December 2021
R-Pharm has supplied to the regions a medicine for treatment of drug-resistant
tuberculosis
13 December 2021
ACR Convergence 2021: R-Pharm presented results of phase III global research
program for rheumatoid arthritis drug, novel IL-6 inhibitor Olokizumab
11 November 2021
Russia`s Health Ministry recommends RA drug olokizumab for patients with
COVID-19 of any severity
11 October 2021
Vladimir Putin congratulated R-Pharm on its 20th anniversary
27 September 2021
A clinical study of the combination of AstraZeneca and Sputnik Light vaccines
in Azerbaijan shows strong neutralizing antibodies growth in the majority
of participants
27 September 2021
R-Pharm employee earned runner-up honors at the EuroSkills 2021 competition
in Austria
26 September 2021
R-Pharm earned runner-up in BRICS Solutions Awards 2021
1 September 2021
A combination of AstraZeneca and the first component of Sputnik V vaccine
(Sputnik Light) demonstrates high immunogenicity profile during the clinical
study in Azerbaijan
20 August 2021
The preliminary results of the world’s first study of AstraZeneca and Sputnik
Light vaccines combination are out
30 July 2021
R-Pharm and Frontier Biotech will provide Russia with a new drug for
the treatment of HIV
13 July 2021
The Russian Ministry of Health has approved pathogenetic treatment
of COVID-19 as an additional indication for olokizumab
17 June 2021
R-Pharm announces the signing of a distribution agreement with PHC Europe B.V.
9 June 2021
R-Pharm and Astec Bio signed an agreement to commercialize the EC6S-230MD®
flatbed incubator for in vitro fertilization procedures
8 June 2021
A novel treatment to manage RA: EULAR key discoveries and prospects for
olokizumab
8 June 2021
R-Pharm and Beijing Health Guard entered into collaboration agreements on the
development and commercialization of a nonavalent HPV vaccine in Russia
28 May 2021
Anti-corruption policy
Antitrust compliance
Code of Business Ethics
Ethics related reporting
Personal data procesing

Designed at Art. Lebedev Studio
Project page
+7 495 956 79 37

info@rpharm.ru

By browsing this site you automatically agree to use cookie files.
Ok